🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 113 of 857 · Phase 3 first, then by program name

  1. Monofer

    Cosmo Technologies Ltd

    Chronic Kidney Disease Stage 5 (Dialysis Dependent)

    phase 3 small molecule completed

    1 trial

  2. Monofer, injektions- og infusionsvæske, opløsning

    Lacuna Pharma Pty Ltd

    Chronic Heart Failure

    phase 3 small molecule active

    1 trial

  3. Mosunetuzumab, Mosunetuzumab

    Hoffmann-La Roche

    NA

    phase 3 small molecule active

    1 trial

  4. Motesanib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule terminated

    1 trial

  5. Motivational interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  6. Mounjaro 5 mg solution for injection in pre-filled pen, cagrilintide semaglutide, cagrilintide semaglutide, Mounjaro 2.5 mg solution for injection in pre-filled pen, cagrilintide semaglutide

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  7. Moxifloxacin

    Pfizer

    Chronic Bronchitis

    phase 3 small molecule completed

    1 trial

  8. Moxifloxacin

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Pulmonary, Drug Sensitive

    phase 3 small molecule completed

    1 trial

  9. Moxifloxacin

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease (COPD).

    phase 3 small molecule active

    1 trial

  10. Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 3 small molecule completed

    1 trial

  11. Multi-centre, Open-label Trial to Assess the SaFety, Pharmacodynamics, Efficacy and Pharmacokinetics of PegunigaLsidase Alfa in Patients from 2 Years to Less Than 18 Years of Age with Confirmed FabrY Disease (FLY)

    Chiesi Farmaceutici S.p.A

    Fabry's disease

    phase 3 other active

    1 trial

  12. Muraglitazar

    Bristol-Myers Squibb

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  13. Mycofit, 250 mg, kapsułki twarde, volrustomig, Saline, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Locally advanced cervical cancer

    phase 3 small molecule active

    1 trial

  14. Mycophenolate Mofetil

    Cardiff Oncology

    Immune Thrombocytopenia

    phase 3 small molecule completed

    1 trial

  15. Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, Lynparza 100 mg film-coated tablets, Myfenax 250 mg hard capsules, Flixabi 100 mg powder for concentrate for solution for infusion, Flixabi 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Imfinzi 50 mg/ml, Lynparza 100 mg, Lynparza 150 mg, Myfenax 250 mg hard capsules, Flixabi 100 mg p

    AstraZeneca AB

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  16. Myocet

    Teva Pharma GmbH

    Early Primary Breast Cancer

    phase 3 small molecule completed

    1 trial

  17. N-Acetyl-L-Leucine, granules for suspension

    Intrabio Ireland Limited

    CACNA1A Disorders

    phase 3 small molecule active

    1 trial

  18. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials

  19. N-Acetylcysteine

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathies

    phase 3 small molecule completed

    1 trial

  20. N-Acetylcysteine (NAC) Treatment

    The First People's Hospital of Lianyungang

    Thrombotic Microangiopathy

    phase 3 small molecule active

    1 trial

  21. N-acetylgalactosamine 4-sulfatase

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis VI

    phase 3 small molecule completed

    3 trials

  22. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  23. NBI-1065845

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  24. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE BIOSCIENCES INC

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources